Known targets — ChEMBL curated mechanism
TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8
The experimentally established mechanism targets of Fosbretabulin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB1 known ✓ | Q9H4B7 | 13/20 | 0.58 |
| ▸ | TUBB4A known ✓ | P04350 | 7/20 | 0.58 |
| ▸ | TUBB known ✓ | P07437 | 7/20 | 0.58 |
| ▸ | TUBA3C known ✓ | P0DPH7 | 7/20 | 0.58 |
| ▸ | TUBA1B known ✓ | P68363 | 7/20 | 0.58 |
| ▸ | TUBA4A known ✓ | P68366 | 7/20 | 0.58 |
| ▸ | TUBB4B known ✓ | P68371 | 7/20 | 0.58 |
| ▸ | TUBB3 known ✓ | Q13509 | 7/20 | 0.58 |
| ▸ | TUBB2A known ✓ | Q13885 | 7/20 | 0.58 |
| ▸ | TUBB8 known ✓ | Q3ZCM7 | 7/20 | 0.58 |
| ▸ | TUBA3E known ✓ | Q6PEY2 | 7/20 | 0.58 |
| ▸ | TUBA1A known ✓ | Q71U36 | 7/20 | 0.58 |
| ▸ | TUBA1C known ✓ | Q9BQE3 | 7/20 | 0.58 |
| ▸ | TUBB6 known ✓ | Q9BUF5 | 7/20 | 0.58 |
| ▸ | TUBB2B known ✓ | Q9BVA1 | 7/20 | 0.58 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.57 |
| ▸ | SLCO2B1 | O94956 | 1/20 | 0.57 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.57 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.57 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fosbretabulin SCHEMBL22527585 | 1.00 | TUBB1 (0.58) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| Fosbretabulin SCHEMBL29379580 | 1.00 | TUBB1 (0.58) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL17146088 | 0.88 | TUBB1 (0.60) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL13479790 | 0.87 | TUBB1 (0.59) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL13940880 | 0.85 | TUBB1 (0.57) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL14175322 | 0.85 | TUBB1 (0.57) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| Fosbretabulin SCHEMBL29374788 | 0.85 | TUBB1 (0.61) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| Fosbretabulin SCHEMBL66079 | 0.85 | TUBB1 (0.61) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| Fosbretabulin SCHEMBL29417596 | 0.85 | TUBB1 (0.61) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL13940886 | 0.85 | TUBB1 (0.61) | TUBB1TUBB4ATUBBTUBA3CTUBA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 309 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090317456-A1 | USE OF ONCOLYTIC VIRUSES AND ANTIANGIOGENIC AGENTS IN THE TREATMENT OF CANCER | MEDIGENE AG (DE) | 2009-12-24 | — | — | US | claimed |
| EP-2073823-A1 | USE OF ONCOLYTIC VIRUSES AND ANTIANGIOGENIC AGENTS IN THE TREATMENT OF CANCER | Medigene AG (DE) | 2009-07-01 | — | — | EP | claimed |
| WO-2008043576-A1 | USE OF ONCOLYTIC VIRUSES AND ANTIANGIOGENIC AGENTS IN THE TREATMENT OF CANCER | MEDIGENE AG (DE) | 2008-04-17 | — | — | WO | claimed |
| US-7358236-B1 | Control of acute hypertension and cardiotoxicity in patients treated with vascular targeting agents | OXIGENE, INC. (US) | 2008-04-15 | — | — | US | claimed |
| US-20070178107-A1 | Method and means for treating solid tumors | AWDALLA ESSAM T | 2007-08-02 | — | — | US | claimed |
| EP-1810680-A2 | Compositions and methods for use in targeting vascular destruction | OXIGENE, INC. (US) | 2007-07-25 | — | — | EP | claimed |
| EP-1351573-A4 | METHODS FOR MODULATING TUMOR GROWTH AND METASTASIS | BRISTOL MYERS SQUIBB CO (US) | 2007-03-28 | — | — | EP | claimed |
| EP-1152764-A4 | COMPOSITIONS AND METHODS FOR USE IN TARGETING VASCULAR DESTRUCTION | OXIGENE INC (US) | 2005-03-23 | — | — | EP | claimed |
| EP-1351573-A1 | METHODS FOR MODULATING TUMOR GROWTH AND METASTASIS | Bristol-Myers Squibb Company (US) | 2003-10-15 | — | — | EP | claimed |
| US-20030109500-A1 | Compositions and methods for use in targeting vascular destruction | MATEON THERAPEUTICS, INC. | 2003-06-12 | — | — | US | claimed |
| US-6538038-B1 | A method of treating a warm-blooded animal having a vascular proliferative disorder, comprising administering, to the animal, an amount of a prodrug of a tubulin binding agent, other than combretastatin A4 disodium phosphate to achieve | OXIGENE, INC. | 2003-03-25 | — | — | US | claimed |
| US-20020160973-A1 | Use of combretastatin A4 and its prodrugs as an immune enhancing therapy | MATEON THERAPEUTICS, INC. | 2002-10-31 | — | — | US | claimed |
| WO-2002058535-A2 | USE OF COMBRETASTATIN A4 AND ITS PRODRUGS AS AN IMMUNE ENHANCING THERAPY | OXIGENE, INC. (US) | 2002-08-01 | — | — | WO | claimed |
| WO-2002056692-A1 | METHODS FOR MODULATING TUMOR GROWTH AND METASTASIS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-07-25 | — | — | WO | claimed |
| EP-1152764-A1 | COMPOSITIONS AND METHODS FOR USE IN TARGETING VASCULAR DESTRUCTION | Oxigene, Inc. (US) | 2001-11-14 | — | — | EP | claimed |
| WO-2000048606-A9 | COMPOSITIONS AND METHODS FOR USE IN TARGETING VASCULAR DESTRUCTION | OXIGENE INC (US) | 2001-10-11 | — | — | WO | claimed |
| WO-2000048606-A1 | COMPOSITIONS AND METHODS FOR USE IN TARGETING VASCULAR DESTRUCTION | OXIGENE, INC. (US) | 2000-08-24 | — | — | WO | claimed |
| US-12636250-B2 | Microneedle array patches (MAPs), systems, and methods for manufacturing and using same | TERRESTRIAL BIO, INC. (US) | 2026-05-26 | — | — | US | disclosed |
| WO-2001000854-A2 | CHIMERIC PROTEINS MEDIATING TARGETED APOPTOSIS | ANGIOGENE PHARMACEUTICALS LIMITED (GB) | 2001-01-04 | — | — | WO | disclosed |
| WO-2000048606-A1 | COMPOSITIONS AND METHODS FOR USE IN TARGETING VASCULAR DESTRUCTION | OXIGENE, INC. (US) | 2000-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12636250-B2 | Microneedle array patches (MAPs), systems, and methods for manufacturing and using same | GLP1R, NPY1R, NPY4R | TUBB1 1976/4885TUBB4A 2787/4885TUBB 2137/4885 |
| US-20030109500-A1 | Compositions and methods for use in targeting vascular destruction | ALPP, MVD, TYMP | TUBB1 1065/4885TUBB4A 1193/4885TUBB 1273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.